Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

| More on:
A cannabis plant grows.

Source: Getty Images

Canopy Growth Corp. (TSX:WEED) has been rallying big time. It has, in fact, more than doubled in the last five days and is up 245% since its March lows. What’s going on? Is Canopy Growth stock finally about to live up to its promise?

While recent developments are somewhat exciting, there’s something I’m still very concerned with. Let’s take a look.

Canopy Growth stock is surging

There’s no denying – recent trading in Canopy Growth stock is quite interesting.

Its days as the investor favourite cannabis stock have been over for quite some time. After its rapid and prolonged downfall and a reverse split, this stock had been languishing. But today, the volatility is back, and this time it’s heading in the right direction again.

Legalization progress

Although news about cannabis legalization settled into the background over the last few years, there have been positive developments on this front.

For example, in March, the German government has approved the legalization of cannabis. As of April 1st, cannabis will be recognized as a non-narcotic. The growth opportunities that this presents to Canopy’s Storz & Bickel brand, as well as its medical cannabis offerings, are significant. Canopy is a top three player in the German cannabis industry.

Furthermore, in the U.S., things seem to be advancing. Even though legalisation has taken longer than many had hoped, the end game seems to be fast approaching. At this time, cannabis is legal in 30 out of 50 states for medical use and 24 states for recreational use. But federal legalization has yet to come.

But they are inching forward. An estimated 88% of Americans support legalization. It seems that President Biden is responding to his voters’ desires and working on reclassifying cannabis to a Schedule 3 drug. This means that the drug has less potential for abuse and an accepted medical use. It’s currently listed as a maximally restricting Schedule 1 drug. This is the same classification as drugs like heroin and ecstasy.  

This reclassification would undoubtedly drive positive momentum for the cannabis industry and cannabis stocks in the United States.

Canopy Growth has been holding on

After its big expansion in the early days of Canadian legalisation, Canopy Growth ran into big problems. Demand was not as strong as many had anticipated, costs were mounting, and the company’s cash burn was placing it in jeopardy.

As a result, Canopy Growth stock has fallen dramatically from its 2018 highs of more than $700. The cannabis industry clearly did not take off as quickly or smoothly as investors were planning. So we’ve been waiting.

The problem

Of course, as I mentioned, there is a problem that I’m concerned about. At this time, revenue growth is weak, net losses are piling up, and the company’s cash burn remains high. In the company’s latest quarterly results, revenue declined 7%, net losses increased to -$2.62 per share, and cash from operations came in at negative $260 million.

Although all of the progress in the legalization effort is good news, the company is still on thin ice. Its cash balance is declining, its debt balance is still high, and profits remain elusive. Canopy Growth stock is a speculative buy at best.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Karen Thomas has no position in any companies mentioned in this article. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Cannabis Stocks

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Could the Cannabis Bubble Re-Inflate?

Let's dive into the question of whether the Canadian cannabis bubble can re-inflate from here.

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

Should You Buy Canopy Growth Stock or Green Thumb Stock Today?

Let's dive into two cannabis giants, and which one may be the better pick for long-term investors.

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Could Aurora Cannabis Stock Finally Recover by Year-End?

Down 99% from all-time highs, Aurora Cannabis stock is focused on improving profit margins and expanding sales of its medical…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Are Pot Stocks About to Surge Again? 

With pot stocks making big moves of late, many investors are now asking whether the cannabis sector is worth investing…

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Can Pot Stocks Aurora Cannabis and Canopy Growth Bounce Back in Q4?

Down over 99% from all-time highs, Canadian pot stocks such as Aurora Cannabis and Canopy Growth remain high-risk bets.

Read more »

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »